Berberine inhibits rat vascular smooth muscle cell proliferation and migration in vitro and improves neointima formation after balloon injury in vivo. Berberine improves neointima formation in a rat model

Atherosclerosis

Volumn 186, Issue 1, 2006, Pages 29-37

  Lee, Seahyoung ^a   Lim, Hyun Joung ^c   Park, Hyun Young ^c   Lee, Kuy Sook ^c   Park, Jin Hee ^c   Jang, Yangsoo ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University   (South Korea)

^c Korea National Institute of Health   (South Korea)

Author keywords

Berberine; Neointima; Vascular smooth muscle cell (VSMC)

Indexed keywords

ANGIOTENSIN II; BERBERINE; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CAROTID ARTERY INJURY; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; IN VITRO STUDY; IN VIVO STUDY; INTIMA; MALE; NONHUMAN; OSMOTIC PUMP; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RAT; RESTENOSIS; TUNICA MEDIA; VASCULAR SMOOTH MUSCLE;

ANGIOPLASTY, BALLOON; ANGIOTENSIN II; ANIMALS; AORTA, THORACIC; BERBERINE; BLOTTING, WESTERN; CAROTID ARTERY INJURIES; CAROTID ARTERY, COMMON; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; EPIDERMAL GROWTH FACTOR; MALE; MUSCLE, SMOOTH, VASCULAR; RATS; RATS, SPRAGUE-DAWLEY; TUNICA INTIMA;

EID: 33646479753     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2005.06.048     Document Type: Article

References (34)

1. Amin A.H., Subbaiah T.V., and Abbasi K.M. Berberine sulfate: antimicrobial activity, bioassay, and mode of action. Can J Microbiol 15 (1969) 1067-1076
2. Rabbani G.H., Butler T., Knight J., Sanyal S.C., and Alam K. Randomized controlled trial of berberine sulfate therapy for diarrhea due to enterotoxigenic Escherichia coli and Vibrio cholerae. J Infect Dis 155 (1987) 979-984
3. Subbaiah T.V., and Amin A.H. Effect of berberine sulphate on Entamoeba histolytica. Nature 215 (1967) 527-528
4. Sun D., Courtney H.S., and Beachey E.H. Berberine sulfate blocks adherence of Streptococcus pyogenes to epithelial cells, fibronectin, and hexadecane. Antimicrob Agents Chemother 32 (1988) 1370-1374
5. Kuo C.L., Chi C.W., and Liu T.Y. The anti-inflammatory potential of berberine in vitro and in vivo. Cancer Lett 203 (2004) 127-137
6. Jantova S., Cipak L., Cernakova M., and Kost'alova D. Effect of berberine on proliferation, cell cycle and apoptosis in HeLa and L1210 cells. J Pharm Pharmacol 55 (2003) 1143-1149
7. Anis K.V., Rajeshkumar N.V., and Kuttan R. Inhibition of chemical carcinogenesis by berberine in rats and mice. J Pharm Pharmacol 53 (2001) 763-768
8. Pan G.Y., Huang Z.J., Wang G.J., et al. The antihyperglycaemic activity of berberine arises from a decrease of glucose absorption. Planta Med 69 (2003) 632-636
9. Leng S.H., Lu F.E., and Xu L.J. Therapeutic effects of berberine in impaired glucose tolerance rats and its influence on insulin secretion. Acta Pharmacol Sin 25 (2004) 496-502
10. Yin J., Hu R., Chen M., et al. Effects of berberine on glucose metabolism in vitro. Metabolism 51 (2002) 1439-1443
11. Yang J., Zhou Z.Y., and Xu J.G. Protective effect of berberine on cardiac hypertrophy induced by L-thyroxine in rats. Sichuan Da Xue Xue Bao Yi Xue Ban 35 (2004) 223-225
12. Hong Y., Hui S.S., Chan B.T., and Hou J. Effect of berberine on catecholamine levels in rats with experimental cardiac hypertrophy. Life Sci 72 (2003) 2499-2507
13. Hong Y., Hui S.C., Chan T.Y., and Hou J.Y. Effect of berberine on regression of pressure-overload induced cardiac hypertrophy in rats. Am J Chin Med 30 (2002) 589-599
14. Zheng L., Zhou Z., Tao D., and Lan T. Protective effect of berberine on cardiac myocyte injured by ischemia-reperfusion. Sichuan Da Xue Xue Bao Yi Xue Ban 34 (2003) 452-454
15. Zeng X.H., Zeng X.J., and Li Y.Y. Efficacy and safety of berberine for congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 92 (2003) 173-176
16. Zhou L.B., Chen M.D., Wang X., et al. Effect of berberine on the differentiation of adipocyte. Zhonghua Yi Xue Za Zhi 83 (2003) 338-340
17. Lau C.W., Yao X.Q., Chen Z.Y., Ko W.H., and Huang Y. Cardiovascular actions of berberine. Cardiovasc Drug Rev 19 (2001) 234-244
18. Kong W., Wei J., Abidi P., et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med 10 (2004) 1344-1351
19. Lin S., Tsai S.C., Lee C.C., et al. Berberine inhibits HIF-1alpha expression via enhanced proteolysis. Mol Pharmacol 66 (2004) 612-619
20. Dimlich R.V., Meineke H.A., Reilly F.D., and McCuskey R.S. The fluorescent staining of heparin in mast cells using berberine sulfate: compatibility with paraformaldehyde or o-phthalaldehyde induced fluorescence and metachromasia. Stain Technol 55 (1980) 217-223
21. Higashiyama S., Abraham J.A., and Klagsbrun M. Heparin-binding EGF-like growth factor stimulation of smooth muscle cell migration: dependence on interactions with cell surface heparan sulfate. J Cell Biol 122 (1993) 933-940
22. Asakura M., Kitakaze M., Takashima S., et al. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat Med 8 (2002) 35-40
23. Inui H., Kitami Y., Kondo T., and Inagami T. Transduction of mitogenic activity of platelet-derived growth factor (PDGF) AB by PDGF-beta receptor without participation of PDGF-alpha receptor in vascular smooth muscle cells. J Biol Chem 268 (1993) 17045-17050
24. Denker S.P., and Barber D.L. Cell migration requires both ion translocation and cytoskeletal anchoring by the Na-H exchanger NHE1. J Cell Biol 159 (2002) 1087-1096
25. Redmond E.M., Cahill P.A., Hirsch M., et al. Effect of pulse pressure on vascular smooth muscle cell migration: the role of urokinase and matrix metalloproteinase. Thromb Haemost 81 (1999) 293-300
26. Kawamura M., Terashita Z., Okuda H., et al. TCV-116, a novel angiotensin II receptor antagonist, prevents intimal thickening and impairment of vascular function after carotid injury in rats. J Pharmacol Exp Ther 266 (1993) 1664-1669
27. Griendling K.K., Ushio-Fukai M., Lassegue B., and Alexander R.W. Angiotensin II signaling in vascular smooth muscle. New concepts. Hypertension 29 (1997) 366-373
28. Li B.X., Yang B.F., Zhou J., Xu C.Q., and Li Y.R. Inhibitory effects of berberine on IK1, IK, and HERG channels of cardiac myocytes. Acta Pharmacol Sin 22 (2001) 125-131
29. Rouzaire-Dubois B., and Dubois J.M. K+ channel block-induced mammalian neuroblastoma cell swelling: a possible mechanism to influence proliferation. J Physiol 510 Pt. 1 (1998) 93-102
30. Eguchi S., Dempsey P.J., Frank G.D., Motley E.D., and Inagami T. Activation of MAPKs by angiotensin II in vascular smooth muscle cells. Metalloprotease-dependent EGF receptor activation is required for activation of ERK and p38 MAPK but not for JNK. J Biol Chem 276 (2001) 7957-7962
31. Busse D., Doughty R.S., Ramsey T.T., et al. Reversible G(1) arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27(KIP1) independent of MAPK activity. J Biol Chem 275 (2000) 6987-6995
32. Schlessinger J., Plotnikov A.N., Ibrahimi O.A., et al. Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Mol Cell 6 (2000) 743-750
33. Yayon A., Klagsbrun M., Esko J.D., Leder P., and Ornitz D.M. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 64 (1991) 841-848
34. Gennaro G., Menard C., Michaud S.E., Deblois D., and Rivard A. Inhibition of vascular smooth muscle cell proliferation and neointimal formation in injured arteries by a novel, oral mitogen-activated protein kinase/extracellular signal-regulated kinase inhibitor. Circulation 110 (2004) 3367-3371